Galapagos NV

Company Description

---

We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Year founded

---

1999

Served area

---

Worldwide

Headquarters

---

Generaal De Wittelaan L11 A3, 2800 Mechelen, Antwerpen – Belgium